Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-21	₩10,860.00	-3.89%	33,814
26-09-18	₩11,300.00	+0.62%	59,021
26-09-17	₩11,230.00	-1.66%	151,035
26-09-16	₩11,420.00	-5.39%	51,092
26-09-15	₩12,070.00	-5.63%	95,058

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 2026-09-21			5-day change	1st Jan Change
10,860.00 ^KRW	-3.89%		-15.09%	+300.00%

Jun. 23	Celemics, Inc. announced that it expects to receive KRW 9.9999956 billion in funding from Cnp Co., Ltd.	CI
May. 28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI

Market Cap	122B 88.9M 77.51M 73M 66.48M 125M 8.52B 125M 874M 337M 4.34B 334M 327M 14B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	117B 84.87M 74M 69.69M 63.47M 119M 8.13B 119M 835M 322M 4.14B 319M 312M 13.37B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	74.26%	Yield 2024 *	-	Yield 2025	-

Jun. 23	Celemics, Inc. announced that it expects to receive KRW 9.9999956 billion in funding from Cnp Co., Ltd.	CI
May. 28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
Apr. 29	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
Apr. 27	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
Mar. 30	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
Mar. 29	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
Mar. 12	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
Feb. 02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
Feb. 02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
22-09-19	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
21-03-22	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
20-08-21	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
20-03-18	Celemics, Inc. has filed an IPO.	CI

1 day	-3.89%
1 week	-15.09%
Current month	-16.91%
1 month	+26.28%
3 months	-16.46%
6 months	+58.77%
Current year	+300.00%

Celemics, Inc. Stock

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news: Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	10,140	12,270
1 month	8,270	15,000
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	20,900
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	2016-12-31
Hyo-Gi Kim CEO	Chief Executive Officer	43	2012-12-31
Sang-Seok Lee PRN	Corporate Officer/Principal	45	2019-12-31

Director	Title	Age	Since
Hyo-Gi Kim BRD	Director/Board Member	43	2012-12-31
Yong-Hun Lee BRD	Director/Board Member	61	2016-12-31
Sang-Seok Lee BRD	Director/Board Member	45	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	-3.89%	-15.09%	+247.52%	+136.34%	88.33M
LONZA GROUP AG	+2.08%	+3.83%	+3.14%	+30.85%	46.68B
IQVIA HOLDINGS INC.	+0.13%	-0.33%	+43.10%	+35.24%	44.42B
REVOLUTION MEDICINES, INC.	-0.23%	-5.05%	+337.99%	+548.37%	41.32B
BEONE MEDICINES AG	-1.48%	+4.40%	+7.08%	+89.81%	41.58B
CELLTRION, INC.	+1.11%	+1.45%	+11.52%	+45.96%	30.14B
MEDPACE HOLDINGS, INC.	-0.08%	-0.07%	+24.49%	+155.49%	17.42B
ASCENDIS PHARMA A/S	+0.26%	-0.53%	-	-	15.6B
EUROFINS SCIENTIFIC SE	+0.77%	+7.00%	+25.43%	+43.31%	15.54B
TEMPUS AI, INC.	+0.72%	+11.48%	-10.61%	-	14.08B
Average	-0.07%	+2.19%	+76.63%	+135.67%	26.69B
Weighted average by Cap.	+0.37%	+2.11%	+69.10%	+144.08%

	2024	2025
Net sales	6.72B 4.89M 4.26M 4.01M 3.66M 6.85M 468M 6.86M 48.07M 18.53M 239M 18.36M 17.95M 770M	5.77B 4.2M 3.66M 3.45M 3.14M 5.88M 402M 5.89M 41.26M 15.9M 205M 15.76M 15.41M 661M
Net income	12.27B 8.92M 7.78M 7.33M 6.67M 12.51M 855M 12.53M 87.75M 33.82M 435M 33.52M 32.77M 1.41B	-4.04B -2.94M -2.56M -2.41M -2.2M -4.12M -281M -4.12M -28.88M -11.13M -143M -11.03M -10.78M -462M
Net Debt	-9.55B -6.95M -6.06M -5.7M -5.19M -9.74M -665M -9.75M -68.31M -26.33M -339M -26.09M -25.51M -1.09B	-5.54B -4.03M -3.51M -3.31M -3.01M -5.65M -386M -5.66M -39.63M -15.28M -197M -15.14M -14.8M -635M